Try as we might, we can’t cover all the biotech news out there! Here’s a roundup of news that didn’t make the cut this week.

Marco Diaz Segura
  • Ablynx received another milestone from MSD for starting an IND-enabling toxicology study
  • Arix Bioscience went in on a $20M Series A for Mitoconix, an Israeli biotech going after Huntinton’s, Parkinson’s and Alzheimer’s Diseases via the mitochondria, and a $45M Series B for LogicBio, based in Cambridge, Massachusetts
  • For its first move since rebranding, LifeArc, formerly MRC Technology, will collaborate with The Centre for Drug Research and Development (CDRD) and the Defence Science and Technology Laboratory (Dstl) on the identification of new antibiotics
  • German generics giant, Stada, failed to gather enough shareholder support for its €5.3B buyout, putting it back on the market
  • Heptares has found a new partner in the New York University School of Medicine for aggressive brain cancer drug discovery, as well as PeptiDream for inflammatory disease
Oleksii G
  • Roche’s antibody for haemophilia A gave a stellar performance that could propel it to blockbuster status
  • Agendia‘s Mammaprint can identify low-risk ‘indolent’ tumors, as described in JAMA Oncology
  • Ablynx has initiated a control Phase I study of caplacizumab
  • Affimed presented preclinical data on its two new NK-cell engagers targeting CD16A
  • Myovant has started a Phase III trial to ease endometriosis-related pain
Brian Lasenby
  • Researchers at the Max Planck Institute in Florida have upgraded optogenetics to work in specific neural circuits
  • While the US Congress isn’t known for getting things done these days, it seems to have its act together to chastise Sanofi for its Zika price hikes

Images from Brian Lasenby, Nirun Thuwasin, Marco Diaz Segura, Oleksii G, Janossy Gergely / shutterstock.com
Previous post

Infographic: Labiotech's Story in a Line 😉

Next post

€40M in Series C for a British Biotech Treating Blindness with Gene Therapy